Autopsy report · NCT03761953

Oritavancin for Staphylococcus Aureus Infections in Opioid Users

“COVID 19 pandemic”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

University of Pennsylvania

Sponsor type

University, hospital or other

Conditions

Staphylococcus Aureus Bacteremia; Staphylococcus Aureus Endocarditis

Interventions

Oritavancin Injection

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Resting Energy Expenditure in Patients With OHS Treated With Long-term NIV
  “COVID pandemic” (90% match in meaning)
• Vitamin C to Reduce Vasopressor Dose in Septic Shock
  “COVID 19” (87% match in meaning)
• High-frequency vs. Low-frequency vs. Sham DMPFC-rTMS for Bulimia and Anorexia Nervosa
  “COVID-19 pandemic restrictions.” (83% match in meaning)
• Effects of Mediterranean Diet Intervention in Diabetic Heart Disease
  “interupted by COVID-19 pandemic” (83% match in meaning)
• Intraocular Pressure and Optic Nerve Sheath Diameter Changes in Laparoscopic Cholecystectomies
  “As a result of COVID-19 pandemics” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.